Abstract | AIM: Effective type 2 diabetes management requires a multifactorial approach extending beyond glycaemic control. Clinical practice guidelines suggest targets for HbA1c, blood pressure and lipids, and emphasize weight reduction and avoiding hypoglycaemia. The phase 3 clinical trial programme for liraglutide, a human glucagon-like peptide 1 analogue, showed significant improvements in HbA1c and weight with a low risk of hypoglycaemia compared to other diabetes therapies. In this context, we performed a meta-analysis of data from these trials evaluating the proportion of patients achieving a clinically relevant composite measure of diabetes control consisting of an HbA1c <7% without weight gain or hypoglycaemia. METHODS: RESULTS: CONCLUSIONS: As assessed by the composite outcome of HbA1c <7%, no hypoglycaemia and no weight gain, liraglutide was clearly superior to the other commonly used therapies. However, the long-term clinical impact of this observation remains to be shown.
|
Authors | B Zinman, W E Schmidt, A Moses, N Lund, S Gough |
Journal | Diabetes, obesity & metabolism
(Diabetes Obes Metab)
Vol. 14
Issue 1
Pg. 77-82
(Jan 2012)
ISSN: 1463-1326 [Electronic] England |
PMID | 21883806
(Publication Type: Journal Article, Meta-Analysis)
|
Copyright | © 2011 Blackwell Publishing Ltd. |
Chemical References |
- Glycated Hemoglobin A
- Hypoglycemic Agents
- Liraglutide
- Glucagon-Like Peptide 1
|
Topics |
- Clinical Trials, Phase III as Topic
- Diabetes Mellitus, Type 2
(blood, drug therapy)
- Female
- Glucagon-Like Peptide 1
(administration & dosage, adverse effects, analogs & derivatives)
- Glycated Hemoglobin
(drug effects)
- Humans
- Hypoglycemia
(blood, chemically induced, prevention & control)
- Hypoglycemic Agents
(administration & dosage, adverse effects)
- Liraglutide
- Male
- Middle Aged
- Weight Gain
(drug effects)
|